Nanobiotix Appoints New CFO Following Five-Year Incumbent's Departure
Nanobiotix (NASDAQ: NANO) announced on October 1, 2026, that its CFO stepped down after five years, succeeded by Arnd Christ. As a Nasdaq-listed biotech, this transition triggers immediate SEC 8-K filing obligations and impacts upcoming 10-Q disclosures.
51CFO view：CFO succession at a Nasdaq-listed biotech requires immediate SOX 302 certification by successor and continuity in R&D expense capitalization judgments. For Chinese biotechs targeting U.S. listing, this highlights need for CFOs with both SEC 10-K signing authority and clinical-stage GAAP accounting expertise.
Nanobiotix (NASDAQ: NANO) announced on October 1, 2026, that its CFO stepped down after five years, succeeded by Arnd Christ. As a Nasdaq-listed biotech, this transition triggers immediate SEC 8-K filing obligations and impacts upcoming 10-Q disclosures.
Source：Google News · CFO 任命